Education
About Us
Working with TipRanks
Follow Us
Protalix Biotherapeutics (PLX)
:PLX
PLX Stock Chart & Stats
$1.73
-$0.05(-2.01%)
At close: 4:00 PM EST
$1.73
-$0.05(-2.01%)
Day’s Range― - ―
52-Week Range$1.32 - $3.10
Previous CloseN/A
Volume368.29K
Average Volume (3M)589.94K
Market Cap
$139.13M
Enterprise Value$158.22M
Total Cash (Recent Filing)$29.37M
Total Debt (Recent Filing)$8.18M
Price to Earnings (P/E)24.9
Beta0.53
Next Earnings
Mar 12, 2026EPS Estimate
0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.03
Shares Outstanding80,421,180
10 Day Avg. Volume480,307
30 Day Avg. Volume589,936
Financial Highlights & Ratios
PEG Ratio-0.70
Price to Book (P/B)3.16
Price to Sales (P/S)2.55
P/FCF Ratio18.45
Enterprise Value/Market Cap1.14
Enterprise Value/Revenue2.56
Enterprise Value/Gross Profit4.45
Enterprise Value/Ebitda17.84
Forecast
1Y Price Target
$12.00Price Target Upside593.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.12
Revenue Forecast (FY)$60.59M
Bulls Say, Bears Say
Bulls Say
Market OpportunityProtalix management indicated that the total Fabry disease market opportunity may raise to $3.1B by 2030, with the potential for the royalty stream from Elfabrio to reach $120-150M per year to the company.
Product ApprovalPegunigalsidase alfa-iwxj is now approved across 23 territories globally for the treatment of Fabry disease.
Revenue GrowthElfabrio royalty-based revenue rises, demonstrating demand.
Bears Say
Revenue MissProtalix reported 1Q25 revenues from selling goods of $10M vs. forecast of $21.6M, attributed to choppiness in royalty-based revenue.
Revenue UncertaintyChoppiness in royalty-based revenue impacted Protalix's financial performance, leading to a significant revenue miss against forecasts.
Protalix News
PLX FAQ
What was Protalix Biotherapeutics’s price range in the past 12 months?
Protalix Biotherapeutics lowest stock price was $1.32 and its highest was $3.10 in the past 12 months.
What is Protalix Biotherapeutics’s market cap?
Protalix Biotherapeutics’s market cap is $139.13M.
When is Protalix Biotherapeutics’s upcoming earnings report date?
Protalix Biotherapeutics’s upcoming earnings report date is Mar 12, 2026 which is in 95 days.
How were Protalix Biotherapeutics’s earnings last quarter?
Protalix Biotherapeutics released its earnings results on Nov 13, 2025. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.055 by -$0.025.
Is Protalix Biotherapeutics overvalued?
According to Wall Street analysts Protalix Biotherapeutics’s price is currently Undervalued.
Does Protalix Biotherapeutics pay dividends?
Protalix Biotherapeutics does not currently pay dividends.
What is Protalix Biotherapeutics’s EPS estimate?
Protalix Biotherapeutics’s EPS estimate is 0.04.
How many shares outstanding does Protalix Biotherapeutics have?
Protalix Biotherapeutics has 80,421,180 shares outstanding.
What happened to Protalix Biotherapeutics’s price movement after its last earnings report?
Protalix Biotherapeutics reported an EPS of $0.03 in its last earnings report, missing expectations of $0.055. Following the earnings report the stock price went down -9.813%.
Which hedge fund is a major shareholder of Protalix Biotherapeutics?
Currently, no hedge funds are holding shares in PLX
Protalix Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.00 (593.64% Upside)
$12.00 (593.64% Upside)
Blogger Sentiment
Bullish
PLX Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $314.2 over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.9%
Last 30 Days ▼ 6.6%
Last 30 Days ▼ 6.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
6.13%
12-Months-Change
Fundamentals
Return on Equity
12.64%
Trailing 12-Months
Asset Growth
33.63%
Trailing 12-Months
Company Description
Protalix Biotherapeutics
Protalix Biotherapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of rare diseases. Utilizing its proprietary ProCellEx protein expression system, Protalix specializes in producing plant-based therapeutic proteins. The company's core products include Elelyso (taliglucerase alfa), an enzyme replacement therapy for Gaucher disease, and other pipeline candidates targeting various disorders.
PLX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong year-to-date revenue growth and advancement in clinical trials, alongside a positive Q3 net income and solid cash position. However, there were challenges, including a slight decrease in Q3 revenue, increased R&D expenses, and regulatory uncertainty regarding Elfabrio's dosing regimen in Europe.View all PLX earnings summariesPLX Stock 12 Month Forecast
Average Price Target
$12.00
▲(593.64% Upside)
Technical Analysis
Coherus Biosciences
―
SELLAS Life Sciences Group
―
Protara Therapeutics
―
Forte Biosciences
―
Innate Pharma
―
Ownership Overview
3.84% Insiders
2.79% Mutual Funds
4.60% Other Institutional Investors
85.00% Public Companies and Individual Investors